(Q38835951)

6 September 2017

1 reference

title

Phenotypes of prediabetes and stratification of cardiometabolic risk (English)

1 reference

6 September 2017

1

1 reference

6 September 2017

4

Hans-Ulrich Häring

1 reference

6 September 2017

3

Fritz Schick

1 reference

6 September 2017

2

Andreas Fritsche

1 reference

6 September 2017

publication date

13 May 2016

1 reference

The Lancet: Diabetes & Endocrinology

6 September 2017

published in

1 reference

6 September 2017

volume

4

1 reference

6 September 2017

issue

9

1 reference

6 September 2017

page(s)

789-798

1 reference

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Global estimates of diabetes prevalence for 2013 and projections for 2035.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Diabetes in China: a societal solution for a personal challenge

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Diabetes: a 21st century challenge

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Definition of intervention points in prediabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Prediabetes: a high-risk state for diabetes development.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Clinical risk factors, DNA variants, and the development of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Glycated hemoglobin measurement and prediction of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Inflammation and metabolic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The cellular and signaling networks linking the immune system and metabolism in disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

What we talk about when we talk about fat.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Diabetes in midlife and cognitive change over 20 years: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Glucose levels and risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Accelerated progression from mild cognitive impairment to dementia in people with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The insulin and insulin-like growth factor receptor family in neoplasia: an update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Prediabetes and the risk of cancer: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Pioglitazone for diabetes prevention in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Effect of nateglinide on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

ER stress in pancreatic beta cells: the thin red line between adaptation and failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The metabolically benign and malignant fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Identification and characterization of metabolically benign obesity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Metabolic and body composition factors in subgroups of obesity: what do we know?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Metabolically healthy and unhealthy obese--the 2013 Stock Conference report

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Causes and metabolic consequences of Fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The Natural Course of Healthy Obesity Over 20 Years

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Incidence of Metabolic Risk Factors Among Healthy Obese Adults: 20-Year Follow-Up.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Adiponectin: mechanistic insights and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Are metabolically healthy obese individuals really healthy?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

The role of hepatokines in metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2816%2900082-6

7 January 2021

10.1016/S2213-8587(16)00082-6

Identifiers

DOI

1 reference

6 September 2017

1 reference